
According to data from Benzinga Pro, during Q1, Pear Therapeutics's (NASDAQ:PEAR) reported sales totaled $2.75 million. Despite a 62.5% increase in earnings, the company posted a loss of $23.86 million. In Q4, Pear Therapeutics brought in $1.32 million in sales but lost $63.63 million in earnings.